NKN. N. Klochkova

N. N. Klochkova

*This is an algorithmically generated author record based on publicly available information.

N. N. Klochkova has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Contrast-enhanced ultrasound of kidney allograft in patient with acute rejection. Case report and literature review

    by N. I. Belavina, S. N. Larionova, N. N. Vetsheva, E. S. Stolyarevich, E. I. Peniaeva, N. N. Klochkova, I. V. Barkova, E. V. Parabina, A. A. Shishimorov, N. F. Frolova

    Kidney transplantation is recognized as the optimal modality of renal replacement therapy. In most cases the diagnosis of the causes of kidney allograft dysfunction and subsequent choice of treatment strategy are determined by the results of nephrobiopsy. The search for alternative noninvasive diagnostic modalities, including ultrasound, that could reveal the specific features of the most common causes of renal graft dysfunction remains relevant. Contrast-enhanced ultrasound (CEUS)is considered a promising modality for the diagnosis of renal graft dysfunction in general and of acute rejection in particular. The article presents the analysis of the results of multiparametric ultrasound in a patient with acute antibody-mediated rejection after voluntary complete withdrawal of immunosuppressive therapy. The subcapsular areas of hypoperfusion were found along with a decrease of allograft perfusion in general. The patterns of “slow wash-in – fast wash-out” of contrast medium in the medulla and “fast wash-out” in the cortex were also detected. The comparison of CEUS and histopathological data from the removed allograft identified the foci of cortical necrosis as the substrate of abnormal perfusion areas. Now it seems premature to evaluate the diagnostic capability of CEUS in complex ultrasound of renal allograft. Further research is necessary to determine the role of CEUS in the complex assessment of kidney transplant pathology.


  • Open Access

    Fulminant emphysematous pyelonephritis in a transplant kidney (clinical observation and literature review)

    by R. N. Trushkin, S. S. Andreev, N. I. Belavina, T. K. Isaev, D. E. Okonskaya, E. S. Stolyarevich, N. N. Klochkova, M. A. Lysenko

    Emphysematous pyelonephritis (EPN) is a necrotizing infection of the renal parenchyma and its surrounding areas that causes gas accumulation around the renal parenchyma, collecting system and surrounding tissues in the process of vital activity of several microorganisms. EPN occurs nearly exclusively in people with diabetes. Treatment strategies for EPN have evolved over the past 20 years, with minimally invasive procedures replacing nephrectomy, which has resulted in lower mortality rates (12.5–13%). EPN is rare in kidney transplant (KT) recipients and is characterized by a severe, often fulminant course with a high rate of adverse outcomes, which is determined primarily by background immunosuppressive therapy. There is no universally accepted consensus on the radiographic classification of EPN in KT recipients and its management. We present the first description of EPN in transplanted kidney in a 45-year-old woman with post-transplant diabetes, obesity and recurrent urinary tract infections. Massive antibiotic therapy (ABT), percutaneous nephrostomy, transplantectomy, renal replacement therapy, selective cytokine adsorption, and ventilatory support were all administered on the patient after she was admitted to the hospital with increasing clinical symptoms of sepsis and multiple organ failure. Death occurred on the fourth day after disease onset. The article examines 38 clinical cases from the English-language segment of the medical literature from the late 1970s to the present. EPN in KT recipients is characterized by the predominance of male gender, including among the deceased, rapid development of sepsis and acute kidney injury. There was no statistically significant difference in the frequency of emergency transplantectomies among surviving and deceased patients. Mortality was 28%. The issue of EPN in transplanted kidney requires more research and the development of optimal therapeutic plans, including surgical strategies.


  • Prediction of COVID-19 course in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus

    by N. N. Klochkova, M. A. Lysenko, Е. М. Зелтынь-Абрамов, T. N. Markova, N. G. Poteshkina, N. I. Belavina, S. V. Kondrashkina

    BACKGROUND.Patients with Diabetes Mellitus 2 (DM2) and Chronic Kidney Disease (CKD) are at a high risk for severe clinical course of COVID-19. The high mortality rate due to COVID-19 and widespread distribution of DM2 and CKD all over the world make it necessary to determine the predictors of adverse outcome of novel coronavirus infection (NCI).AIM.The identification of predictors of NCI adverse outcome in patients with DM2 and CKD stage 3 due to diabetic kidney disease.Patients and Methods. The patients with NCI and CKD stage 3 were included in observational retrospective uncontrolled study during the follow-up period from 04.01. to 10.30.2020. The study endpoints were the outcome of NCI (survivors/nonsurvivors). Data were collected from electronic versions of case records. Demographic, DM2-related, CKD-related and NCI-related baseline parameters/signs were studied as independent variables.RESULTS.90 patients with DM2 and CKD stages 3 (Me GFR 43[37; 49] ml/ min/1,73m2) were included, mean age 70 [69; 78] y, females – 56 %, the mortality rate – 21 %. The independent predictors of NCI adverse outcome were detected using a single factor analysis (odds ratio). Among them are: initial prandial glycemia ≥ 10 mmol/l (ОR 11,8; 95 % CI 3,13–44,9; р CONCLUSION. The detected predictors of adverse outcome are the part of routine screening available in pre-hospital setting and at hospital admission. Early identification of predictors allows optimizing patient routing and selecting the best treatment strategy for each patient.

  • Ultrasound examination of failed renal transplant in patients with graft intolerance syndrome. Case series

    by Moscow City Hospital 52, N.I. Belavina, Trushkin, L.Yu. Artyukhina, Moscow City Hospital 52; A.I. Evdokimov Moscow State University of Medicine and Dentistry, E.S. Ivanova, E.S. Stolyarevich, Moscow City Hospital 52; A.I. Evdokimov Moscow State University of Medicine and Dentistry; Shumakov National Medical Research Center of Transplantology and Artificial Organs, O.V. Manchenko, T.K. Isaev, et al.


  • COVID-19 in patients with advanced stages of diabetic kidney disease: new onset renal replacement therapy as one of the predictors of adverse outcome

    by State Budgetary Healthcare Institution “City Clinical Hospital 52” of Moscow Healthcare Department, N.N. Klochkova, Pirogov Russian National Research Medical University (Pirogov Medical University), M.A. Lysenko, State Budgetary Healthcare Institution “City Clinical Hospital 52” of Moscow Healthcare Department; Pirogov Russian National Research Medical University (Pirogov Medical University), E.M. Zeltyn-Abramov, T.N. Markova, State Budgetary Healthcare Institution “City Clinical Hospital 52” of Moscow Healthcare Department; A.I. Yevdokimov Moscow State University of Medicine and Dentistr, N.G. Poteshkina, N.I. Belavina, et al.


  • Open Access

    COVID-19-Associated Biventricular Takotsubo Syndrome Complicated with Cardiogenic Shock (Clinical Case)

    by Е. М. Зелтынь-Абрамов, N. I. Belavina, N. N. Klochkova, R. T. Iskhakov, O. Yu. Evsyukov, L. Yu. Аrtyukhina, A. M. Svanadze, M. A. Lysenko

    Среди внелегочных проявлений COVID-19 важное место занимает острая миокардиальная дисфункция. Одной из причин ее развития является синдром Такоцубо (СТ). Частота встречаемости СТ у пациентов с COVID-19 неизвестна. Представлено клиническое наблюдение пожилой пациентки с тяжелым течением COVID-19, получавшей лечение программным гемодиализом. В ходе сеанса терапевтического плазмообмена развился эпизод фибрилляции желудочков с формированием клинико-инструментальной картины кардиогенного шока, сопровождавшейся инфарктоподобными изменениями ЭКГ. По данным Эхо-КГ выявлен типичный паттерн бивентрикулярного СТ с выраженным снижением систолической функции обоих желудочков. По результатам экстренной коронароангиографии обструктивного поражения коронарного русла не выявлено. В течение последующей недели лечения отмечались полное восстановление систолической функции обоих желудочков, регресс инфарктоподобных изменений ЭКГ и разрешение кардиогенного шока. Дальнейшее течение заболевания осложнилось развитием сепсиса и полиорганной недостаточности, приведших к летальному исходу. По данным аутопсии коронарогенное и вирусное поражение миокарда были исключены. Представленный случай демонстрирует развитие жизнеугрожающего варианта СТ у пациентки с COVID-19. В качестве вероятного триггера следует рассматривать процедуру терапевтического плазмообмена.

  • Open Access

    Risk factors of adverse outcome of COVID-19 and experience of Tocilizumab administration in patients on maintenance hemodialysis due to diabetic kidney disease

    by Е. М. Зелтынь-Абрамов, M. A. Lysenko, N. F. Frolova, T. N. Markova, N. I. Belavina, N. N. Klochkova, S. V. Kondrashkina, R. T. Iskhakov, A. I. Ushakova

    BACKGROUND: Patients with Type 2 Diabetes (T2DM) and patients on maintenance hemodialysis (MHD) are at a high risk of adverse clinical course of COVID-19. To date, the causes of high mortality in these groups are not fully understood. Data about peculiarity of clinical course and Tocilizumab (TCZ) administration in patients with T2DM receiving MHD due to outcome of diabetic kidney disease (DKD) are not yet highlighted in current publications.AIMS: Identification of risk factors (RF) of adverse COVID-19 outcome and evaluation of TCZ administration in patients with T2DM receiving MHD due to DKD.MATERIALS AND METHODS: The patients treated in Moscow City Hospital No52 were included in retrospective observational study. The observation period was from 04.15 to 07.30 2020. The study endpoints were the outcomes of hospitalization — discharge or lethal outcome. Data were collected from electronic medical database. The following independent variables were analysed: gender, age, body mass index, time from the onset of symptoms to hospital admission, cardiovascular and general comorbidity (Charlson Index, CCI), cardiovascular event (CVE) during hospitalization, treatment in ICU, mechanical ventilation (MV), degree of lung damage according to CT data, level of prandial glycemia at admission, MHDassociated parameters (vintage, type of vascular access, frequency of complications). The autopsy reports were evaluated for the purpose of lethal structure investigation. In a subgroup treated TCZ the time from symptoms onset to TCZ administration and number of laboratory indicators were evaluated.RESULTS: 53 patients were included, mean age 68 ±9 y, males — 49%. General mortality in observation cohort was 45%, mortality in ICU — 81%, mortality on MV — 95%. High cardiovascular and general comorbidity was revealed (mean CCI — 8,3 ±1,5 points). The causes of outcomes according to autopsy reports data: CVE 37,5% (among them — acute myocardial infarction during hospitalization), severe respiratory failure — 62,5%. The independent predictors of lethal outcome were: MV (OR 106; 95% CI 11,5–984; р CONCLUSIONS: The number of RF of adverse COVID-19 outcome in patients with T2DM receiving MHD due to DKD are identified. CVE is one of the leading causes of mortality in study cohort. According to our experience the preventive (instead of rescue) strategy of TCZ administration should be used.